OA10977A - Substituted 6,5-hetero-bicyclic derivatives - Google Patents

Substituted 6,5-hetero-bicyclic derivatives Download PDF

Info

Publication number: OA10977A
Authority: OA; OAPI
Prior art keywords: phenyl; trimethyl; stress; compounds; ethyl
Prior art date: 1996-08-28

Application number

OA9900035A

Other languages

English (en)

Inventor

Chen Yuhpyng Liang

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-08-28

Filing date

1999-02-17

Publication date

2001-11-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21823717&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA10977(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-02-17 Application filed by Pfizer filed Critical Pfizer

2001-11-02 Publication of OA10977A publication Critical patent/OA10977A/en

Links

150000001875 compounds Chemical class 0.000 claims abstract description 181
229910052799 carbon Inorganic materials 0.000 claims abstract description 36
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 30
229910052757 nitrogen Inorganic materials 0.000 claims abstract description 19
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 12
230000003042 antagnostic effect Effects 0.000 claims abstract description 3
230000005764 inhibitory process Effects 0.000 claims abstract description 3
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 51
239000000203 mixture Substances 0.000 claims description 42
-1 tri-substitutedphenyl Chemical group 0.000 claims description 35
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 34
125000000217 alkyl group Chemical group 0.000 claims description 27
238000000034 method Methods 0.000 claims description 26
208000035475 disorder Diseases 0.000 claims description 25
125000001309 chloro group Chemical group Cl* 0.000 claims description 24
125000001246 bromo group Chemical group Br* 0.000 claims description 21
229910052684 Cerium Inorganic materials 0.000 claims description 20
102100021752 Corticoliberin Human genes 0.000 claims description 20
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 19
125000001153 fluoro group Chemical group F* 0.000 claims description 16
125000002346 iodo group Chemical group I* 0.000 claims description 15
125000004093 cyano group Chemical group *C#N 0.000 claims description 14
239000001257 hydrogen Substances 0.000 claims description 14
229910052739 hydrogen Inorganic materials 0.000 claims description 14
208000011580 syndromic disease Diseases 0.000 claims description 13
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 12
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
101710113174 Corticoliberin Proteins 0.000 claims description 10
229940079593 drug Drugs 0.000 claims description 10
239000003814 drug Substances 0.000 claims description 10
201000010099 disease Diseases 0.000 claims description 9
208000026278 immune system disease Diseases 0.000 claims description 9
208000002551 irritable bowel syndrome Diseases 0.000 claims description 9
150000002431 hydrogen Chemical class 0.000 claims description 8
230000003961 neuronal insult Effects 0.000 claims description 8
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
208000019022 Mood disease Diseases 0.000 claims description 7
208000028867 ischemia Diseases 0.000 claims description 7
241000725303 Human immunodeficiency virus Species 0.000 claims description 6
241000124008 Mammalia Species 0.000 claims description 6
208000008589 Obesity Diseases 0.000 claims description 6
125000003545 alkoxy group Chemical group 0.000 claims description 6
229940088597 hormone Drugs 0.000 claims description 6
239000005556 hormone Substances 0.000 claims description 6
235000020824 obesity Nutrition 0.000 claims description 6
208000024827 Alzheimer disease Diseases 0.000 claims description 5
206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 5
206010012335 Dependence Diseases 0.000 claims description 5
208000030814 Eating disease Diseases 0.000 claims description 5
208000019454 Feeding and Eating disease Diseases 0.000 claims description 5
208000018522 Gastrointestinal disease Diseases 0.000 claims description 5
206010019196 Head injury Diseases 0.000 claims description 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
206010020772 Hypertension Diseases 0.000 claims description 5
208000001132 Osteoporosis Diseases 0.000 claims description 5
201000004681 Psoriasis Diseases 0.000 claims description 5
206010037660 Pyrexia Diseases 0.000 claims description 5
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 5
208000005392 Spasm Diseases 0.000 claims description 5
206010046543 Urinary incontinence Diseases 0.000 claims description 5
208000006673 asthma Diseases 0.000 claims description 5
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
108091008324 binding proteins Proteins 0.000 claims description 5
235000014632 disordered eating Nutrition 0.000 claims description 5
206010015037 epilepsy Diseases 0.000 claims description 5
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
208000015181 infectious disease Diseases 0.000 claims description 5
208000000509 infertility Diseases 0.000 claims description 5
230000036512 infertility Effects 0.000 claims description 5
231100000535 infertility Toxicity 0.000 claims description 5
208000027866 inflammatory disease Diseases 0.000 claims description 5
230000002401 inhibitory effect Effects 0.000 claims description 5
208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 5
230000004770 neurodegeneration Effects 0.000 claims description 5
208000015122 neurodegenerative disease Diseases 0.000 claims description 5
230000037324 pain perception Effects 0.000 claims description 5
208000028173 post-traumatic stress disease Diseases 0.000 claims description 5
239000000126 substance Substances 0.000 claims description 5
206010002027 Amyotrophy Diseases 0.000 claims description 4
208000020925 Bipolar disease Diseases 0.000 claims description 4
206010007559 Cardiac failure congestive Diseases 0.000 claims description 4
208000011231 Crohn disease Diseases 0.000 claims description 4
241000283073 Equus caballus Species 0.000 claims description 4
206010015549 Euthyroid sick syndrome Diseases 0.000 claims description 4
241000287828 Gallus gallus Species 0.000 claims description 4
206010019233 Headaches Diseases 0.000 claims description 4
206010019280 Heart failures Diseases 0.000 claims description 4
GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims description 4
208000023105 Huntington disease Diseases 0.000 claims description 4
206010020751 Hypersensitivity Diseases 0.000 claims description 4
206010028980 Neoplasm Diseases 0.000 claims description 4
208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 4
208000002193 Pain Diseases 0.000 claims description 4
208000018737 Parkinson disease Diseases 0.000 claims description 4
241001494479 Pecora Species 0.000 claims description 4
208000028017 Psychotic disease Diseases 0.000 claims description 4
206010039966 Senile dementia Diseases 0.000 claims description 4
208000025865 Ulcer Diseases 0.000 claims description 4
201000011510 cancer Diseases 0.000 claims description 4
206010061592 cardiac fibrillation Diseases 0.000 claims description 4
235000013330 chicken meat Nutrition 0.000 claims description 4
206010061428 decreased appetite Diseases 0.000 claims description 4
229960002069 diamorphine Drugs 0.000 claims description 4
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
231100000318 excitotoxic Toxicity 0.000 claims description 4
230000003492 excitotoxic effect Effects 0.000 claims description 4
230000002600 fibrillogenic effect Effects 0.000 claims description 4
231100000869 headache Toxicity 0.000 claims description 4
208000014674 injury Diseases 0.000 claims description 4
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
230000036407 pain Effects 0.000 claims description 4
208000019899 phobic disease Diseases 0.000 claims description 4
230000002980 postoperative effect Effects 0.000 claims description 4
125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
230000008733 trauma Effects 0.000 claims description 4
231100000397 ulcer Toxicity 0.000 claims description 4
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical class N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims description 3
241000283690 Bos taurus Species 0.000 claims description 3
206010006550 Bulimia nervosa Diseases 0.000 claims description 3
125000006519 CCH3 Chemical group 0.000 claims description 3
241000282472 Canis lupus familiaris Species 0.000 claims description 3
206010012289 Dementia Diseases 0.000 claims description 3
125000002947 alkylene group Chemical group 0.000 claims description 3
230000007815 allergy Effects 0.000 claims description 3
230000003993 interaction Effects 0.000 claims description 3
201000008482 osteoarthritis Diseases 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
229920006395 saturated elastomer Polymers 0.000 claims description 3
208000019116 sleep disease Diseases 0.000 claims description 3
210000000278 spinal cord Anatomy 0.000 claims description 3
208000024891 symptom Diseases 0.000 claims description 3
208000000103 Anorexia Nervosa Diseases 0.000 claims description 2
208000008939 Pneumonic Pasteurellosis Diseases 0.000 claims description 2
208000001871 Tachycardia Diseases 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
230000004064 dysfunction Effects 0.000 claims description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 claims description 2
230000006794 tachycardia Effects 0.000 claims description 2
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 16
208000019901 Anxiety disease Diseases 0.000 claims 2
206010039073 rheumatoid arthritis Diseases 0.000 claims 2
102000014914 Carrier Proteins Human genes 0.000 claims 1
201000009916 Postpartum depression Diseases 0.000 claims 1
241001247203 Syngnathidae Species 0.000 claims 1
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
230000001314 paroxysmal effect Effects 0.000 claims 1
125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
125000005958 tetrahydrothienyl group Chemical group 0.000 claims 1
ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical group [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims 1
229910052760 oxygen Inorganic materials 0.000 abstract description 9
239000001301 oxygen Substances 0.000 abstract description 4
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 3
229910052717 sulfur Inorganic materials 0.000 abstract description 3
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
239000011593 sulfur Substances 0.000 abstract 1
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 42
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 33
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 32
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 22
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 21
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 20
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 20
239000003921 oil Substances 0.000 description 20
235000019198 oils Nutrition 0.000 description 20
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
239000002253 acid Substances 0.000 description 18
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
239000012442 inert solvent Substances 0.000 description 15
239000012044 organic layer Substances 0.000 description 15
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 14
239000002585 base Substances 0.000 description 14
238000006243 chemical reaction Methods 0.000 description 13
238000010992 reflux Methods 0.000 description 13
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 12
239000003480 eluent Substances 0.000 description 12
238000010438 heat treatment Methods 0.000 description 12
239000000243 solution Substances 0.000 description 12
229960000583 acetic acid Drugs 0.000 description 11
150000001412 amines Chemical class 0.000 description 11
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 11
239000007787 solid Substances 0.000 description 11
239000002904 solvent Substances 0.000 description 11
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 10
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 10
235000011054 acetic acid Nutrition 0.000 description 10
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
239000011734 sodium Substances 0.000 description 9
239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 8
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
238000002360 preparation method Methods 0.000 description 8
229910052708 sodium Inorganic materials 0.000 description 8
229910000104 sodium hydride Inorganic materials 0.000 description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
239000012267 brine Substances 0.000 description 6
AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 6
LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 6
239000011541 reaction mixture Substances 0.000 description 6
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
229910000147 aluminium phosphate Inorganic materials 0.000 description 5
244000309464 bull Species 0.000 description 5
238000004440 column chromatography Methods 0.000 description 5
239000000499 gel Substances 0.000 description 5
239000010410 layer Substances 0.000 description 5
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
239000012312 sodium hydride Substances 0.000 description 5
DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 4
101150041968 CDC13 gene Proteins 0.000 description 4
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
239000005557 antagonist Substances 0.000 description 4
102000023732 binding proteins Human genes 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(ii) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 4
230000000694 effects Effects 0.000 description 4
150000002148 esters Chemical class 0.000 description 4
239000005457 ice water Substances 0.000 description 4
ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
229910052700 potassium Inorganic materials 0.000 description 4
239000011591 potassium Substances 0.000 description 4
125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 4
125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 4
125000001424 substituent group Chemical group 0.000 description 4
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 3
JQJPBYFTQAANLE-UHFFFAOYSA-N Butyl nitrite Chemical compound CCCCON=O JQJPBYFTQAANLE-UHFFFAOYSA-N 0.000 description 3
208000001640 Fibromyalgia Diseases 0.000 description 3
239000007818 Grignard reagent Substances 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
239000002841 Lewis acid Substances 0.000 description 3
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
208000006011 Stroke Diseases 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
230000029936 alkylation Effects 0.000 description 3
238000005804 alkylation reaction Methods 0.000 description 3
239000000969 carrier Substances 0.000 description 3
USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 3
150000004795 grignard reagents Chemical class 0.000 description 3
150000007517 lewis acids Chemical class 0.000 description 3
QUSNBJAOOMFDIB-UHFFFAOYSA-N monoethyl amine Natural products CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 3
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 3
125000004076 pyridyl group Chemical group 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
239000000741 silica gel Substances 0.000 description 3
229910002027 silica gel Inorganic materials 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
239000008096 xylene Substances 0.000 description 3
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 2
YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 2
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
229910021590 Copper(II) bromide Inorganic materials 0.000 description 2
206010012735 Diarrhoea Diseases 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
208000011688 Generalised anxiety disease Diseases 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
208000005314 Multi-Infarct Dementia Diseases 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
235000019502 Orange oil Nutrition 0.000 description 2
235000019483 Peanut oil Nutrition 0.000 description 2
244000000231 Sesamum indicum Species 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
201000004810 Vascular dementia Diseases 0.000 description 2
WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical compound CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 description 2
150000004703 alkoxides Chemical class 0.000 description 2
150000001351 alkyl iodides Chemical class 0.000 description 2
239000011260 aqueous acid Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
206010003246 arthritis Diseases 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
125000001589 carboacyl group Chemical group 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
208000026725 cyclothymic disease Diseases 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000012039 electrophile Substances 0.000 description 2
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
208000029364 generalized anxiety disease Diseases 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
229910052744 lithium Inorganic materials 0.000 description 2
UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 2
WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 2
239000000463 material Substances 0.000 description 2
150000004702 methyl esters Chemical class 0.000 description 2
229960002715 nicotine Drugs 0.000 description 2
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 2
239000010502 orange oil Substances 0.000 description 2
239000000312 peanut oil Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
229910000027 potassium carbonate Inorganic materials 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
239000000047 product Substances 0.000 description 2
WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
125000003373 pyrazinyl group Chemical group 0.000 description 2
238000010791 quenching Methods 0.000 description 2
230000000171 quenching effect Effects 0.000 description 2
238000010898 silica gel chromatography Methods 0.000 description 2
239000012279 sodium borohydride Substances 0.000 description 2
229910000033 sodium borohydride Inorganic materials 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
CAWZOADDWCXSEF-UHFFFAOYSA-N triazolo[4,5-b]pyridine Chemical compound [CH]1C=CN=C2N=NN=C21 CAWZOADDWCXSEF-UHFFFAOYSA-N 0.000 description 2
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
SYSFTTYJTWPOOR-UHFFFAOYSA-N (2-diphenylphosphanyl-1-naphthalen-1-yl-3h-naphthalen-2-yl)-diphenylphosphane Chemical group C1C=C2C=CC=CC2=C(C=2C3=CC=CC=C3C=CC=2)C1(P(C=1C=CC=CC=1)C=1C=CC=CC=1)P(C=1C=CC=CC=1)C1=CC=CC=C1 SYSFTTYJTWPOOR-UHFFFAOYSA-N 0.000 description 1
XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 description 1
NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical compound C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 1
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
XBYRMPXUBGMOJC-UHFFFAOYSA-N 1,2-dihydropyrazol-3-one Chemical class OC=1C=CNN=1 XBYRMPXUBGMOJC-UHFFFAOYSA-N 0.000 description 1
FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
RSEXIAXAURZHHJ-UHFFFAOYSA-N 2,5-dimethyl-4-pentan-3-yloxy-7-(2,4,6-trimethylphenyl)-6h-pyrrolo[3,4-b]pyridine Chemical compound N1C(C)=C2C(OC(CC)CC)=CC(C)=NC2=C1C1=C(C)C=C(C)C=C1C RSEXIAXAURZHHJ-UHFFFAOYSA-N 0.000 description 1
KSPFHCHNABIANX-UHFFFAOYSA-N 3-(4-chloro-2,6-dimethylphenyl)-5-methyl-n-pentan-3-ylpyrazolo[1,5-a]pyrimidin-7-amine Chemical compound C1=NN2C(NC(CC)CC)=CC(C)=NC2=C1C1=C(C)C=C(Cl)C=C1C KSPFHCHNABIANX-UHFFFAOYSA-N 0.000 description 1
QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
KQEZZLOQANKDBC-UHFFFAOYSA-N 3-oxo-2-(2,4,6-trimethylphenyl)propanenitrile Chemical compound CC1=CC(C)=C(C(C=O)C#N)C(C)=C1 KQEZZLOQANKDBC-UHFFFAOYSA-N 0.000 description 1
125000001054 5 membered carbocyclic group Chemical group 0.000 description 1
KWTSGGLVCPQKSJ-UHFFFAOYSA-N 5-methyl-7-pentan-3-yloxy-3-(2,4,6-trimethylphenyl)-[1,2]thiazolo[4,5-b]pyridine Chemical compound N=1SC=2C(OC(CC)CC)=CC(C)=NC=2C=1C1=C(C)C=C(C)C=C1C KWTSGGLVCPQKSJ-UHFFFAOYSA-N 0.000 description 1
HQDCRCUUIUKXED-UHFFFAOYSA-N 6-methyl-4-pentan-3-yloxy-2-n-(2,4,6-trimethylphenyl)pyridine-2,3-diamine Chemical compound CCC(CC)OC1=CC(C)=NC(NC=2C(=CC(C)=CC=2C)C)=C1N HQDCRCUUIUKXED-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 1
101100298226 Arabidopsis thaliana POT3 gene Proteins 0.000 description 1
101150047265 COR2 gene Proteins 0.000 description 1
101100115215 Caenorhabditis elegans cul-2 gene Proteins 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
229940122010 Corticotropin releasing factor antagonist Drugs 0.000 description 1
108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 1
102100032165 Corticotropin-releasing factor-binding protein Human genes 0.000 description 1
VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 1
XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
101100260565 Dictyostelium discoideum thyA gene Proteins 0.000 description 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
206010013883 Dwarfism Diseases 0.000 description 1
101100001669 Emericella variicolor andD gene Proteins 0.000 description 1
101100001672 Emericella variicolor andG gene Proteins 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
241000282412 Homo Species 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
208000013016 Hypoglycemia Diseases 0.000 description 1
241000845077 Iare Species 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
NMMIHXMBOZYNET-UHFFFAOYSA-N Methyl picolinate Chemical compound COC(=O)C1=CC=CC=N1 NMMIHXMBOZYNET-UHFFFAOYSA-N 0.000 description 1
WRQNANDWMGAFTP-UHFFFAOYSA-N Methylacetoacetic acid Chemical compound COC(=O)CC(C)=O WRQNANDWMGAFTP-UHFFFAOYSA-N 0.000 description 1
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
206010034912 Phobia Diseases 0.000 description 1
206010036618 Premenstrual syndrome Diseases 0.000 description 1
208000033641 Ring chromosome 5 syndrome Diseases 0.000 description 1
229910006074 SO2NH2 Inorganic materials 0.000 description 1
101100467189 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) QCR2 gene Proteins 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
235000003434 Sesamum indicum Nutrition 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
241000700605 Viruses Species 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000001350 alkyl halides Chemical class 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
125000002619 bicyclic group Chemical group 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
229960003920 cocaine Drugs 0.000 description 1
238000004040 coloring Methods 0.000 description 1
229940125846 compound 25 Drugs 0.000 description 1
239000010949 copper Substances 0.000 description 1
DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
239000002769 corticotropin releasing factor antagonist Substances 0.000 description 1
108010083720 corticotropin releasing factor-binding protein Proteins 0.000 description 1
239000012043 crude product Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
230000005595 deprotonation Effects 0.000 description 1
238000010537 deprotonation reaction Methods 0.000 description 1
HMOJUCUJIXEKOH-UHFFFAOYSA-N dicyanoalumanylformonitrile Chemical compound N#C[Al](C#N)C#N HMOJUCUJIXEKOH-UHFFFAOYSA-N 0.000 description 1
GGSUCNLOZRCGPQ-UHFFFAOYSA-N diethylaniline Chemical compound CCN(CC)C1=CC=CC=C1 GGSUCNLOZRCGPQ-UHFFFAOYSA-N 0.000 description 1
FOBPTJZYDGNHLR-UHFFFAOYSA-N diphosphorus Chemical compound P#P FOBPTJZYDGNHLR-UHFFFAOYSA-N 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
125000006575 electron-withdrawing group Chemical group 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
239000000284 extract Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000012458 free base Substances 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
125000001072 heteroaryl group Chemical group 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
230000000971 hippocampal effect Effects 0.000 description 1
IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
150000004678 hydrides Chemical class 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
230000008629 immune suppression Effects 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
239000008101 lactose Substances 0.000 description 1
CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 1
YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
230000036651 mood Effects 0.000 description 1
HKKXCQVMQMJDSE-UHFFFAOYSA-N n,n-diethyl-2,5-dimethyl-3-(2,4,6-trimethylphenyl)pyrazolo[1,5-a]pyrimidin-7-amine Chemical compound CC1=NN2C(N(CC)CC)=CC(C)=NC2=C1C1=C(C)C=C(C)C=C1C HKKXCQVMQMJDSE-UHFFFAOYSA-N 0.000 description 1
JEUXZUSUYIHGNL-UHFFFAOYSA-N n,n-diethylethanamine;hydrate Chemical compound O.CCN(CC)CC JEUXZUSUYIHGNL-UHFFFAOYSA-N 0.000 description 1
SFQADZSWHHFASC-UHFFFAOYSA-N n-ethyl-6-methyl-n-propyl-3-(2,4,6-trimethylphenyl)-[1,2,4]triazolo[4,3-b]pyridazin-8-amine Chemical compound N=1N=C2C(N(CC)CCC)=CC(C)=NN2C=1C1=C(C)C=C(C)C=C1C SFQADZSWHHFASC-UHFFFAOYSA-N 0.000 description 1
XCVNDBIXFPGMIW-UHFFFAOYSA-N n-ethylpropan-1-amine Chemical compound CCCNCC XCVNDBIXFPGMIW-UHFFFAOYSA-N 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
125000000962 organic group Chemical group 0.000 description 1
125000001979 organolithium group Chemical group 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
WXHIJDCHNDBCNY-UHFFFAOYSA-N palladium dihydride Chemical compound [PdH2] WXHIJDCHNDBCNY-UHFFFAOYSA-N 0.000 description 1
MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 1
YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
208000019906 panic disease Diseases 0.000 description 1
PQPFFKCJENSZKL-UHFFFAOYSA-N pentan-3-amine Chemical compound CCC(N)CC PQPFFKCJENSZKL-UHFFFAOYSA-N 0.000 description 1
125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
FVZVCSNXTFCBQU-UHFFFAOYSA-N phosphanyl Chemical group [PH2] FVZVCSNXTFCBQU-UHFFFAOYSA-N 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000137 polyphosphoric acid Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
229910000105 potassium hydride Inorganic materials 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
238000000746 purification Methods 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
125000006085 pyrrolopyridyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
125000005493 quinolyl group Chemical group 0.000 description 1
238000006268 reductive amination reaction Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
239000003488 releasing hormone Substances 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
102200073741 rs121909602 Human genes 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
235000010288 sodium nitrite Nutrition 0.000 description 1
YHOBGCSGTGDMLF-UHFFFAOYSA-N sodium;di(propan-2-yl)azanide Chemical compound [Na+].CC(C)[N-]C(C)C YHOBGCSGTGDMLF-UHFFFAOYSA-N 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
125000004434 sulfur atom Chemical group 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 1
101150068774 thyX gene Proteins 0.000 description 1
125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
125000005270 trialkylamine group Chemical group 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
238000001665 trituration Methods 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
238000010626 work up procedure Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Addiction (AREA)
Immunology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Reproductive Health (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Virology (AREA)
Gynecology & Obstetrics (AREA)
Dermatology (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
Communicable Diseases (AREA)

OA9900035A 1996-08-28 1999-02-17 Substituted 6,5-hetero-bicyclic derivatives OA10977A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US2503996P	1996-08-28	1996-08-28

Publications (1)

Publication Number	Publication Date
OA10977A true OA10977A (en)	2001-11-02

Family

ID=21823717

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA9900035A OA10977A (en)	1996-08-28	1999-02-17	Substituted 6,5-hetero-bicyclic derivatives

Country Status (36)

Country	Link
EP (1)	EP0923582B1 (is)
JP (2)	JP3621706B2 (is)
KR (1)	KR20000035934A (is)
CN (1)	CN1227554A (is)
AP (1)	AP762A (is)
AR (1)	AR015103A1 (is)
AT (1)	ATE340176T1 (is)
AU (1)	AU735401B2 (is)
BG (1)	BG103189A (is)
BR (1)	BR9711970A (is)
CA (1)	CA2263566C (is)
CO (1)	CO4600634A1 (is)
CZ (1)	CZ68199A3 (is)
DE (1)	DE69736711T2 (is)
DZ (1)	DZ2300A1 (is)
EA (1)	EA002769B1 (is)
ES (1)	ES2273369T3 (is)
GT (1)	GT199700095A (is)
HR (1)	HRP970454B1 (is)
HU (1)	HUP9903965A3 (is)
ID (1)	ID18249A (is)
IL (1)	IL127566A0 (is)
IS (1)	IS4963A (is)
MA (1)	MA26438A1 (is)
NO (1)	NO313636B1 (is)
NZ (1)	NZ333302A (is)
OA (1)	OA10977A (is)
PA (1)	PA8436201A1 (is)
PE (1)	PE108898A1 (is)
PL (1)	PL332040A1 (is)
SK (1)	SK23399A3 (is)
TN (1)	TNSN97145A1 (is)
TR (1)	TR199900389T2 (is)
TW (1)	TW575573B (is)
WO (1)	WO1998008847A1 (is)
ZA (1)	ZA977687B (is)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2194756A1 (en)	1995-05-12	1996-11-14	Jun Yuan	Novel deazapurine derivatives; a new class of crf1 specific ligands
US6060478A (en) *	1996-07-24	2000-05-09	Dupont Pharmaceuticals	Azolo triazines and pyrimidines
US6191131B1 (en)	1997-07-23	2001-02-20	Dupont Pharmaceuticals Company	Azolo triazines and pyrimidines
US6124289A (en) *	1996-07-24	2000-09-26	Dupont Pharmaceuticals Co.	Azolo triazines and pyrimidines
US7094782B1 (en)	1996-07-24	2006-08-22	Bristol-Myers Squibb Company	Azolo triazines and pyrimidines
US6313124B1 (en)	1997-07-23	2001-11-06	Dupont Pharmaceuticals Company	Tetrazine bicyclic compounds
CA2281525A1 (en)	1997-02-18	1998-08-20	Neurocrine Biosciences, Inc.	Biazacyclic crf antagonists
JP2002501493A (ja) *	1997-04-22	2002-01-15	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	Ｃｒｆアンタゴニストのチオフェノピリジン類
CN1268137A (zh) *	1997-07-03	2000-09-27	杜邦药品公司	治疗神经失调的咪唑并嘧啶和咪唑并吡啶
EP1049699B1 (en) *	1998-01-28	2004-04-21	Bristol-Myers Squibb Pharma Company	Pyrazolotriazines as crf antagonists
US6187777B1 (en)	1998-02-06	2001-02-13	Amgen Inc.	Compounds and methods which modulate feeding behavior and related diseases
US6472402B1 (en)	1998-04-02	2002-10-29	Neurogen Corporation	Aminoalkyl substituted 5,6,7,8-Tetrahydro-9H-Pyridino [2,3-B]indole derivatives
EP1068205A1 (en)	1998-04-02	2001-01-17	Neurogen Corporation	Aminoalkyl substituted 5,6,7,8-tetrahydro-9h pyrimidino 2,3-b]indole and 5,6,7,8-tetrahydro-9h-pyrimidino 4,5-b]indole derivatives: crf1 specific ligands
AU3213699A (en) *	1998-04-03	1999-10-25	Du Pont Pharmaceuticals Company	Thiazolo(4,5-d)pyrimidines and pyridines as corticotropin releasing factor (CRF)antagonists
CA2334671A1 (en) *	1998-06-09	1999-12-16	Neurogen Corporation	Pyrido[2,3-b]indolizine derivatives and aza analogues thereof; crf1 specific ligands
US6509338B1 (en)	1998-06-22	2003-01-21	Bristol-Myers Squibb Company	Pyrazolo[1,5-A]triazine corticotropin releasing factor antagonists
CA2339188A1 (en)	1998-08-21	2000-03-02	Dupont Pharmaceuticals Company	Isoxazolo¬4,5-d\|pyrimidines as crf antagonists
US6531475B1 (en) *	1998-11-12	2003-03-11	Neurocrine Biosciences, Inc.	CRF receptor antagonists and methods relating thereto
PT1129096E (pt)	1998-11-12	2003-09-30	Neurocrine Biosciences Inc	Antagonistas de receptor de crf e metodos de tratamento relacionados com os mesmos
PT1129091E (pt) *	1998-11-12	2003-02-28	Neurocrine Biosciences Inc	Antagonistas de receptor de crf e metodos relacionados
EP1149835A4 (en) *	1999-01-29	2002-08-21	Sumitomo Chemical Co	AGENTS FOR INHIBITATION OF FAT
EP1040831A3 (en) *	1999-04-02	2003-05-02	Pfizer Products Inc.	Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
AU4203500A (en)	1999-04-06	2000-10-23	Du Pont Pharmaceuticals Company	Pyrazolopyrimidines as crf antagonists
WO2000059907A2 (en)	1999-04-06	2000-10-12	Du Pont Pharmaceuticals Company	Pyrazolotriazines as crf antagonists
EP1669071B1 (en) *	1999-05-21	2009-07-22	Bristol-Myers Squibb Company	Pyrrolotriazine inhibitors of kinases
US6982265B1 (en)	1999-05-21	2006-01-03	Bristol Myers Squibb Company	Pyrrolotriazine inhibitors of kinases
US6432989B1 (en) *	1999-08-27	2002-08-13	Pfizer Inc	Use of CRF antagonists to treat circadian rhythm disorders
JP2003510325A (ja)	1999-09-30	2003-03-18	ニューロジェン・コーポレーション	ある種のアルキレンジアミン−置換ピラゾロ［１，５−ａ］−１，５−ピリミジン及びピラゾロ［１，５−ａ］−１，３，５−トリアジン
ES2258476T3 (es)	1999-09-30	2006-09-01	Neurogen Corporation	Ciertos heterociclos sustituidos con alquilendiaminas.
SE9903544D0 (sv)	1999-10-01	1999-10-01	Astra Pharma Prod	Novel compounds
IL139197A0 (en)	1999-10-29	2001-11-25	Pfizer Prod Inc	Use of corticotropin releasing factor antagonists and related compositions
TWI271406B (en)	1999-12-13	2007-01-21	Eisai Co Ltd	Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
EP1257555B1 (en) *	2000-02-11	2003-12-03	AstraZeneca AB	Pyrimidine compounds and their use as modulators of chemokine receptor activity
GB2359081A (en) *	2000-02-11	2001-08-15	Astrazeneca Uk Ltd	Pharmaceutically active thiazolopyrimidines
GB2359078A (en) *	2000-02-11	2001-08-15	Astrazeneca Uk Ltd	Pharmaceutically active pyrimidine derivatives
CA2398956A1 (en) *	2000-02-14	2001-08-16	Japan Tobacco Inc.	A pharmaceutical composition for prophylaxis or therapy of a postoperative stress
GB2359551A (en)	2000-02-23	2001-08-29	Astrazeneca Uk Ltd	Pharmaceutically active pyrimidine derivatives
EP1149583A3 (en) *	2000-04-13	2001-11-14	Pfizer Products Inc.	Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues
EP1287002A1 (en)	2000-05-18	2003-03-05	Neurocrine Biosciences, Inc.	Crf receptor antagonists
AU2001259707A1 (en)	2000-06-14	2001-12-24	Warner Lambert Company	6,5-fused bicyclic heterocycles
US6630476B2 (en) *	2000-07-07	2003-10-07	Bristol-Myers Squibb Pharma Company	Pyrrolo [3,4-d] pyrimidines as corticotropin releasing factor (CRF) antagonists
SE0003828D0 (sv)	2000-10-20	2000-10-20	Astrazeneca Ab	Novel compounds
US6867300B2 (en)	2000-11-17	2005-03-15	Bristol-Myers Squibb Company	Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
HUP0303653A3 (en)	2000-12-28	2006-05-29	Ono Pharmaceutical Co	Tricyclic and heterocyclic derivative and pharmaceutical compositions containing them as the active ingredient
GB0100624D0 (en) *	2001-01-10	2001-02-21	Vernalis Res Ltd	Chemical compounds VII
TWI312347B (en) *	2001-02-08	2009-07-21	Eisai R&D Man Co Ltd	Bicyclic nitrogen-containing condensed ring compounds
IL157615A0 (en) *	2001-03-13	2004-03-28	Bristol Myers Squibb Co	4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo-[1,5-a]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands
SE0101322D0 (sv)	2001-04-12	2001-04-12	Astrazeneca Ab	Novel compounds
RU2308457C2 (ru)	2001-04-27	2007-10-20	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Пиразоло [1, 5-а] пиридины и содержащие их лекарственные средства
KR20040018260A (ko) *	2001-05-21	2004-03-02	뉴로크린 바이오사이언시즈 인코퍼레이티드	Ｃｒｆ 수용체 길항제로서의 트리- 및테트라아자-아세나프틸렌 유도체
GB0117396D0 (en)	2001-07-17	2001-09-05	Glaxo Group Ltd	Chemical compounds
EP2335700A1 (en)	2001-07-25	2011-06-22	Boehringer Ingelheim (Canada) Ltd.	Hepatitis C virus polymerase inhibitors with a heterobicylic structure
TW200300350A (en)	2001-11-14	2003-06-01	Bristol Myers Squibb Co	C-5 modified indazolylpyrrolotriazines
EP1485385B1 (en)	2002-03-07	2005-08-17	SmithKline Beecham Corporation	Pyrazolopyrimidine and pyrazolotriazine derivatives and pharmaceutical compositions containing them
EP1348707B1 (en) *	2002-03-28	2010-08-25	Ustav Experimentalni Botaniky AV CR, v.v.i. (Institute of Experimental Botany Academy of Sciences of the Czech Republic, PRO)	Pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy
US7119200B2 (en) *	2002-09-04	2006-10-10	Schering Corporation	Pyrazolopyrimidines as cyclin dependent kinase inhibitors
GB0221828D0 (en)	2002-09-20	2002-10-30	Astrazeneca Ab	Novel compound
AR041470A1 (es)	2002-10-17	2005-05-18	Upjohn Co	Compuestos de pirrolo (1,2 - b) piridazina y sus usos
US7176216B2 (en)	2002-10-22	2007-02-13	Eisai Co., Ltd.	7-phenylpyrazolopyridine compounds
TWI283679B (en)	2002-10-22	2007-07-11	Eisai Co Ltd	7-phenylpyrazolopyridine compounds
TW200420565A (en)	2002-12-13	2004-10-16	Bristol Myers Squibb Co	C-6 modified indazolylpyrrolotriazines
KR101078098B1 (ko)	2003-01-14	2011-10-28	아레나 파마슈티칼스, 인크.	대사 조절제로서의 １,２,３-삼치환된 아릴 및 헤테로아릴유도체, 및 당뇨병 및 고혈당증을 비롯한 이에 관련된장애의 예방 및 치료
KR101312736B1 (ko) *	2003-02-27	2013-09-27	팔라우 파르마 에스에이	피라졸로피리딘 유도체
US7041671B2 (en)	2003-04-02	2006-05-09	Pfizer Inc	Pyrrolo[1,2-b]pyridazine compounds and their uses
US7034023B2 (en)	2003-04-04	2006-04-25	Pfizer Inc	Pyrrolo[1,2-B]pyridazine compounds and their uses
US7056920B2 (en) *	2003-04-04	2006-06-06	Pfizer Inc	Pyrrolo[1,2-B]pyridazine compounds and their uses
GB0308208D0 (en)	2003-04-09	2003-05-14	Glaxo Group Ltd	Chemical compounds
BRPI0409444A (pt) *	2003-04-15	2006-04-18	Pharmacia & Upjohn Co Llc	compostos de pirrolo[1,2-b]piridazina e suas utilizações
EP1620437B1 (en)	2003-04-29	2009-06-17	Pfizer Limited	5,7-diaminopyrazolo¬4,3-d pyrimidines useful in the traetment of hypertension
MXPA05011993A (es) *	2003-05-07	2006-02-02	Pharmacia & Upjohn Co Llc	Compuestos de pirrolo[1,2-b]piridazina.
WO2004110454A1 (ja) *	2003-06-13	2004-12-23	Ishihara Sangyo Kaisha, Ltd.	アデノシンＡ2ａ受容体アゴニストの投与が必要な疾患を治療又は予防するための組成物
AR045047A1 (es)	2003-07-11	2005-10-12	Arena Pharm Inc	Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
AR045697A1 (es)	2003-07-14	2005-11-09	Arena Pharm Inc	Aril y heteroaril derivados fusionados como moduladores del metabolismo y la prevencion y tratamiento de trastornos relacionados con el mismo
AP2006003559A0 (en) *	2003-09-05	2006-04-30	Neurogen Corp Ventis Pharmaceuticals Inc	Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF 1 receptor ligands
US7208596B2 (en)	2003-11-25	2007-04-24	Bristol-Myers Squibb Pharma Company	Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof
US7153961B2 (en)	2003-11-25	2006-12-26	Bristol-Myers Squibb Pharma Co.	Salt and crystalline form thereof of a corticotropin releasing factor receptor antagonist
GB0328243D0 (en)	2003-12-05	2004-01-07	Astrazeneca Ab	Methods
US7102001B2 (en)	2003-12-12	2006-09-05	Bristol-Myers Squibb Company	Process for preparing pyrrolotriazine
AR046967A1 (es)	2003-12-22	2006-01-04	Sb Pharmco Inc	Compuesto de pirazol[1,5-a]pirimidina, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
US7064203B2 (en)	2003-12-29	2006-06-20	Bristol Myers Squibb Company	Di-substituted pyrrolotriazine compounds
MY145634A (en)	2003-12-29	2012-03-15	Bristol Myers Squibb Co	Pyrrolotriazine compounds as kinase inhibitors
CA2552503C (en)	2004-01-06	2011-09-13	Taisho Pharmaceutical Co., Ltd.	Pyrrolopyrimidine and pyrrolotriazine derivatives
US7557111B2 (en)	2004-01-06	2009-07-07	Taisho Pharmaceutical Co., Ltd.	Substituted thieno[3,2-d]pyrimidines as CRF receptor antagonists
TWI368507B (en)	2004-02-20	2012-07-21	Boehringer Ingelheim Int	Viral polymerase inhibitors
US7102002B2 (en)	2004-06-16	2006-09-05	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
US7102003B2 (en)	2004-07-01	2006-09-05	Bristol-Myers Squibb Company	Pyrrolotriazine compounds
US7504521B2 (en)	2004-08-05	2009-03-17	Bristol-Myers Squibb Co.	Methods for the preparation of pyrrolotriazine compounds
US7148348B2 (en)	2004-08-12	2006-12-12	Bristol-Myers Squibb Company	Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
DE602005014375D1 (de) *	2004-10-19	2009-06-18	Neurocrine Biosciences Inc	Crf-rezeptor-antagonisten und zugehörige verfahren
GB0519957D0 (en)	2005-09-30	2005-11-09	Sb Pharmco Inc	Chemical compound
US7151176B2 (en)	2004-10-21	2006-12-19	Bristol-Myers Squibb Company	Pyrrolotriazine compounds
KR20070100237A (ko)	2004-10-29	2007-10-10	바이오크리스트 파마수티컬즈, 인코퍼레이티드	치료용 푸로피리미딘 및 티에노피리미딘
US7674822B2 (en)	2004-11-24	2010-03-09	Wyeth	PTP1b inhibitors
CA2602533A1 (en)	2005-03-29	2006-10-05	Biocryst Pharmaceuticals, Inc.	Use of c-nucleoside analogs for treatment of hepatitis c related viral infections
JPWO2006126718A1 (ja) *	2005-05-27	2008-12-25	田辺三菱製薬株式会社	ピラゾロピリミジン誘導体
TW200740820A (en)	2005-07-05	2007-11-01	Takeda Pharmaceuticals Co	Fused heterocyclic derivatives and use thereof
EP1915377A1 (en)	2005-07-22	2008-04-30	Sunesis Pharmaceuticals, Inc.	Pyrazolo pyrimidines useful as aurora kinase inhibitors
US20070078136A1 (en)	2005-09-22	2007-04-05	Bristol-Myers Squibb Company	Fused heterocyclic compounds useful as kinase modulators
US7514435B2 (en)	2005-11-18	2009-04-07	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
US8063208B2 (en)	2006-02-16	2011-11-22	Bristol-Myers Squibb Company	Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol
CA2663511C (en)	2006-09-20	2012-12-04	Eli Lilly And Company	Thiazole pyrazolopyrimidines as crf1 receptor antagonists
MX2009003098A (es)	2006-09-20	2009-04-01	Lilly Co Eli	Compuestos de tiofen pirazolopirimidina.
NZ576278A (en)	2006-10-19	2011-12-22	Signal Pharm Llc	Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
CN101932583A (zh)	2007-12-19	2010-12-29	沃泰克斯药物股份有限公司	用作JAK2抑制剂的吡唑并[1,5-a]嘧啶类
US8324241B2 (en)	2008-04-11	2012-12-04	Bristol-Myers Squibb Company	Triazolo compounds useful as DGAT1 inhibitors
WO2009126861A2 (en)	2008-04-11	2009-10-15	Bristol-Myers Squibb Company	Triazolopyridine compounds useful as dgat1 inhibitors
BRPI0911659B8 (pt)	2008-04-15	2021-05-25	Eisai R&D Man Co Ltd	composto 3-fenilpirazolo[5,1-b]tiazol e composição farmacêutica compreendendo o mesmo
GB0906579D0 (en)	2009-04-16	2009-05-20	Vernalis R&D Ltd	Pharmaceuticals, compositions and methods of making and using the same
TWI491610B (zh)	2008-10-09	2015-07-11	必治妥美雅史谷比公司	作為激酶抑制劑之咪唑并嗒腈
AR078521A1 (es)	2009-10-08	2011-11-16	Eisai R&D Man Co Ltd	Compuesto pirazolotiazol
WO2011101644A1 (en)	2010-02-18	2011-08-25	Centro Nacional De Investigaciones Oncologicas (Cnio)	Triazolo [4, 5 - b] pyridin derivatives
US8912184B1 (en)	2010-03-01	2014-12-16	Alzheimer's Institute Of America, Inc.	Therapeutic and diagnostic methods
CN102933584A (zh) *	2010-04-16	2013-02-13	Abbvie公司	激酶的吡咯并吡嗪酮抑制剂
JP5583845B2 (ja)	2010-04-28	2014-09-03	ブリストル−マイヤーズスクイブカンパニー	イミダゾピリダジニル化合物および癌に対するそれらの使用
TWI541243B (zh)	2010-09-10	2016-07-11	拜耳知識產權公司	經取代咪唑并嗒
SG188548A1 (en)	2010-09-22	2013-04-30	Arena Pharm Inc	Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012064815A1 (en)	2010-11-12	2012-05-18	Bristol-Myers Squibb Company	Substituted azaindazole compounds
EP2651948A1 (en)	2010-12-17	2013-10-23	Bayer Intellectual Property GmbH	Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders
JP5824065B2 (ja)	2010-12-17	2015-11-25	バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＧｍｂＨ	過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための６置換イミダゾピラジン
CN103370322B (zh)	2010-12-17	2016-02-10	拜耳知识产权有限责任公司	在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的2-取代的咪唑并吡嗪
KR101946499B1 (ko)	2011-04-08	2019-02-11	얀센 사이언시즈 아일랜드 언리미티드 컴퍼니	바이러스 감염 치료를 위한 피리미딘 유도체
WO2012149157A2 (en) *	2011-04-26	2012-11-01	Bioenergenix	Heterocyclic compounds for the inhibition of pask
WO2013049263A1 (en)	2011-09-27	2013-04-04	Bristol-Myers Squibb Company	Substituted bicyclic heteroaryl compounds
EP2776439B1 (en)	2011-11-09	2018-07-04	Janssen Sciences Ireland UC	Purine derivatives for the treatment of viral infections
JP6166289B2 (ja)	2012-03-14	2017-07-19	バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＧｍｂＨ	置換イミダゾピリダジン
WO2014009305A1 (en) *	2012-07-09	2014-01-16	Janssen Pharmaceutica Nv	Inhibitors of phosphodiesterase 10 enzyme
CA2874800C (en)	2012-07-13	2021-04-06	Janssen R&D Ireland	Macrocyclic purines for the treatment of viral infections
WO2014020041A1 (en)	2012-08-02	2014-02-06	Bayer Pharma Aktiengesellschaft	Combinations for the treatment of cancer
NZ705589A (en)	2012-10-10	2019-05-31	Janssen Sciences Ireland Uc	Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
US9278973B2 (en)	2012-10-25	2016-03-08	Bioenergenix Llc	Heterocyclic compounds for the inhibition of PASK
WO2014066795A1 (en)	2012-10-25	2014-05-01	Bioenergenix	Heterocyclic compounds for the inhibition of pask
AU2013346793B2 (en)	2012-11-16	2018-03-08	Janssen Sciences Ireland Uc	Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
KR102225233B1 (ko)	2013-02-21	2021-03-09	얀센 사이언시즈 아일랜드 언리미티드 컴퍼니	바이러스 감염의 치료를 위한 2-아미노피리미딘 유도체
EP2970307B1 (en)	2013-03-13	2020-03-11	Genentech, Inc.	Pyrazolo compounds and uses thereof
MX366481B (es)	2013-03-29	2019-07-09	Janssen Sciences Ireland Uc	Deaza-purinonas macrociclicas para el tratamiento de infecciones virales.
MY188071A (en)	2013-05-24	2021-11-16	Janssen Sciences Ireland Uc	Pyridone derivatives for the treatment of viral infections and further diseases
PT3008062T (pt)	2013-06-11	2017-06-07	Bayer Pharma AG	Derivados de profármaco de triazolopiridinas substituídas
CN109369643B (zh) *	2013-06-27	2021-05-18	爱尔兰詹森科学公司	用于治疗病毒感染和其他疾病的吡咯并[3,2-d]嘧啶衍生物
EP3027624B1 (en)	2013-07-30	2018-09-12	Janssen Sciences Ireland UC	Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
EP2940022B1 (en) *	2014-04-30	2020-09-02	Masarykova Univerzita	Furopyridines as inhibitors of protein kinases
PL3242666T3 (pl)	2015-01-06	2025-02-17	Arena Pharmaceuticals, Inc.	Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
HUE060476T2 (hu)	2015-06-22	2023-03-28	Arena Pharm Inc	(R)-2-(7-(4-ciklopentil-3-(trifluormetil)benziloxi)-1,2,3,4- tetrahidrociklopenta[B]indol-3-il)ecetsav kristályos L-arginin-sója S1P1 receptorral kapcsolatos rendellenességek esetén való alkalmazásra
RU2699568C2 (ru) *	2015-12-21	2019-09-06	Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова"	Лиганды транслокаторного белка TSPO, обладающие антидепрессивной и ноотропной активностью
WO2018002319A1 (en)	2016-07-01	2018-01-04	Janssen Sciences Ireland Uc	Dihydropyranopyrimidines for the treatment of viral infections
WO2018060317A1 (en)	2016-09-29	2018-04-05	Janssen Sciences Ireland Uc	Pyrimidine prodrugs for the treatment of viral infections and further diseases
CN118845788A (zh)	2017-08-14	2024-10-29	云杉生物科学公司	促肾上腺皮质激素释放因子受体拮抗剂
TW202415645A (zh)	2018-03-01	2024-04-16	愛爾蘭商健生科學愛爾蘭無限公司	２，４－二胺基喹唑啉衍生物及其醫學用途
MX2020011344A (es)	2018-04-27	2021-02-09	Spruce Biosciences Inc	Métodos para tratar tumores en reposo suprarrenales testiculares y de ovarios.
US12156866B2 (en)	2018-06-06	2024-12-03	Arena Pharmaceuticals, Inc.	Methods of treating conditions related to the S1P1 receptor
CN108812546A (zh) *	2018-09-07	2018-11-16	四川省草原科学研究院	适于青藏高原地区牦牛运输减少应激的药物及使用方法
CN118948857A (zh)	2020-08-12	2024-11-15	云杉生物科学公司	用于治疗多囊卵巢综合征的方法和组合物
US11708372B2 (en)	2021-11-19	2023-07-25	Spruce Biosciences, Inc.	Crystalline composition of tildacerfont and methods of use and preparation thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW574214B (en) *	1994-06-08	2004-02-01	Pfizer	Corticotropin releasing factor antagonists
CA2194756A1 (en) *	1995-05-12	1996-11-14	Jun Yuan	Novel deazapurine derivatives; a new class of crf1 specific ligands

1997
- 1997-07-25 ES ES97930697T patent/ES2273369T3/es not_active Expired - Lifetime
- 1997-07-25 CA CA002263566A patent/CA2263566C/en not_active Expired - Fee Related
- 1997-07-25 IL IL12756697A patent/IL127566A0/xx unknown
- 1997-07-25 AU AU34561/97A patent/AU735401B2/en not_active Ceased
- 1997-07-25 DE DE69736711T patent/DE69736711T2/de not_active Expired - Fee Related
- 1997-07-25 NZ NZ333302A patent/NZ333302A/xx unknown
- 1997-07-25 KR KR1019997001674A patent/KR20000035934A/ko not_active Ceased
- 1997-07-25 BR BR9711970A patent/BR9711970A/pt not_active Application Discontinuation
- 1997-07-25 AT AT97930697T patent/ATE340176T1/de not_active IP Right Cessation
- 1997-07-25 EA EA199900165A patent/EA002769B1/ru not_active IP Right Cessation
- 1997-07-25 TR TR1999/00389T patent/TR199900389T2/xx unknown
- 1997-07-25 JP JP51142998A patent/JP3621706B2/ja not_active Expired - Fee Related
- 1997-07-25 PL PL97332040A patent/PL332040A1/xx unknown
- 1997-07-25 WO PCT/IB1997/000922 patent/WO1998008847A1/en not_active Ceased
- 1997-07-25 CN CN97197027A patent/CN1227554A/zh active Pending
- 1997-07-25 CZ CZ99681A patent/CZ68199A3/cs unknown
- 1997-07-25 EP EP97930697A patent/EP0923582B1/en not_active Revoked
- 1997-07-25 HU HU9903965A patent/HUP9903965A3/hu unknown
- 1997-07-25 SK SK233-99A patent/SK23399A3/sk unknown
- 1997-08-12 PA PA19978436201A patent/PA8436201A1/es unknown
- 1997-08-21 AP APAP/P/1997/001077A patent/AP762A/en active
- 1997-08-22 HR HR970454A patent/HRP970454B1/xx not_active IP Right Cessation
- 1997-08-25 PE PE1997000756A patent/PE108898A1/es not_active Application Discontinuation
- 1997-08-25 TW TW086112194A patent/TW575573B/zh active
- 1997-08-25 GT GT199700095A patent/GT199700095A/es unknown
- 1997-08-26 ID IDP972962A patent/ID18249A/id unknown
- 1997-08-26 AR ARP970103861A patent/AR015103A1/es not_active Application Discontinuation
- 1997-08-27 TN TNTNSN97145A patent/TNSN97145A1/fr unknown
- 1997-08-27 DZ DZ970150A patent/DZ2300A1/fr active
- 1997-08-27 ZA ZA977687A patent/ZA977687B/xx unknown
- 1997-08-27 MA MA24779A patent/MA26438A1/fr unknown
- 1997-08-28 CO CO97049895A patent/CO4600634A1/es unknown
1999
- 1999-01-29 IS IS4963A patent/IS4963A/is unknown
- 1999-02-17 OA OA9900035A patent/OA10977A/en unknown
- 1999-02-22 BG BG103189A patent/BG103189A/xx unknown
- 1999-02-26 NO NO19990927A patent/NO313636B1/no not_active IP Right Cessation
2004
- 2004-09-21 JP JP2004273978A patent/JP2005047930A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
HUP9903965A3 (en)	2002-02-28
AP9701077A0 (en)	1997-10-31
IS4963A (is)	1999-01-29
GT199700095A (es)	1999-02-16
HRP970454B1 (en)	2002-10-31
AP762A (en)	1999-09-13
EA002769B1 (ru)	2002-08-29
WO1998008847A1 (en)	1998-03-05
DE69736711D1 (de)	2006-11-02
ID18249A (id)	1998-03-19
PA8436201A1 (es)	1999-12-27
CN1227554A (zh)	1999-09-01
PE108898A1 (es)	1999-01-26
DZ2300A1 (fr)	2002-12-25
ATE340176T1 (de)	2006-10-15
PL332040A1 (en)	1999-08-16
CA2263566C (en)	2003-09-09
EA199900165A1 (ru)	1999-08-26
NO990927D0 (no)	1999-02-26
BG103189A (en)	1999-09-30
BR9711970A (pt)	1999-08-24
DE69736711T2 (de)	2007-09-20
HUP9903965A2 (hu)	2000-03-28
CZ68199A3 (cs)	1999-11-17
AR015103A1 (es)	2001-04-18
ES2273369T3 (es)	2007-05-01
JP3621706B2 (ja)	2005-02-16
NZ333302A (en)	2000-08-25
TW575573B (en)	2004-02-11
EP0923582A1 (en)	1999-06-23
NO990927L (no)	1999-02-26
TR199900389T2 (xx)	2000-06-21
IL127566A0 (en)	1999-10-28
JP2005047930A (ja)	2005-02-24
CA2263566A1 (en)	1998-03-05
AU3456197A (en)	1998-03-19
CO4600634A1 (es)	1998-05-08
AU735401B2 (en)	2001-07-05
JP2000502723A (ja)	2000-03-07
KR20000035934A (ko)	2000-06-26
HRP970454A2 (en)	1998-08-31
ZA977687B (en)	1999-03-01
EP0923582B1 (en)	2006-09-20
MA26438A1 (fr)	2004-12-20
SK23399A3 (en)	2000-08-14
NO313636B1 (no)	2002-11-04
TNSN97145A1 (fr)	2005-03-15

Publication	Publication Date	Title
OA10977A (en)	2001-11-02	Substituted 6,5-hetero-bicyclic derivatives
US6900217B2 (en)	2005-05-31	Substituted 6,5-hetero-bicyclic derivatives
CA2262692C (en)	2002-06-11	Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives
JP5972964B2 (ja)	2016-08-17	抗腫瘍剤としての三環式および四環式ピラゾロ［３，４−ｂ］ピリジン化合物
AP1164A (en)	2003-06-30	Substituted 6,6-hetero-bicyclic derivatives.
EP3532473B1 (en)	2021-09-29	Heterobicyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
AU2021373162A1 (en)	2023-04-13	Pyrazolopyridazinone compound, and pharmaceutical composition and use thereof
CN108137552A (zh)	2018-06-08	作为人免疫缺陷病毒复制的抑制剂的5-(n-稠合三环芳基四氢异喹啉-6-基)吡啶-3-基乙酸衍生物
JP2023541465A (ja)	2023-10-02	カゼインキナーゼ１デルタモジュレーター
JP2023528907A (ja)	2023-07-06	大環状構造を有する化合物及びその使用
US3929787A (en)	1975-12-30	6,7,8,9-Tetrahydro-pyrido(1,2-a)pyrimidin-4-ones
MXPA99002014A (en)	1999-06-01	Substituted 6,5-hetero-bicyclic derivatives
CN106946909A (zh)	2017-07-14	抗肺结核病的硝基咪唑衍生物
Ahmed	2002	A Convenient Synthesis for Some New Pyrido [4′, 3′: 4, 5] thieno [2, 3-d] pyrimidines and Related Fused 1, 2, 4-Triazolo and 1, 3, 4-Thiadiazolo-derivatives
WO2026064285A1 (en)	2026-03-26	Insulin growth factor-1 receptor (igf-1r) inhibitors and methods of uses thereof
MXPA99001309A (en)	1999-06-01	Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives